株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

前立腺癌:BRICにおける治療薬の予測と治療分析(〜2020年)

Prostate Cancer - BRIC Drug Forecasts and Treatment Analysis to 2020

発行 GlobalData 商品コード 139848
出版日 ページ情報 英文 243 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
前立腺癌:BRICにおける治療薬の予測と治療分析(〜2020年) Prostate Cancer - BRIC Drug Forecasts and Treatment Analysis to 2020
出版日: 2010年12月01日 ページ情報: 英文 243 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、BRICにおける前立腺癌治療薬市場の動向と競合、パイプライン分析、参入企業のプロファイル、アンメットニーズ、開発中の薬剤動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 疾病の概要

  • 概要
  • 疫学
  • 病因
  • 症状
  • 診断
  • 病理学
  • 治療
  • 治療ガイドライン

第3章 市場の特性

  • BRIC
  • ブラジル
  • ロシア
  • インド
  • 中国

第4章 競合評価

  • 戦略的競合評価
  • 製品プロファイル

第5章 パイプライン評価

  • 概要
  • 開発段階別パイプライン分析
  • 作用機序別パイプライン
  • 戦略的パイプライン評価
  • 前立腺癌パイプライン動向
  • 研究開発パートナー
  • 最も有望な薬剤プロファイル
  • 前治験段階
  • 第1相
  • 第2相
  • 第3相

第6章 アンメットニーズと標的製品プロファイル

第7章 戦略的評価

第8章 企業プロファイル

第9章 M&A動向

第10章 専門家の見解

第11章 付録

図表

目次
Product Code: GDHC009DFR

Abstract

Prostate Cancer - BRIC Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData' s pharmaceutical report, “Prostate Cancer - Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020” is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. It analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- An overview of prostate cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized prostate cancer therapeutics market revenue, the annual cost of therapy and treatment usage patterns (for hormone therapy and hormone resistant or refractory therapy) for the BRIC countries from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals and life cycle management activities.
- Analysis of unmet need in the market and target product profiles including the opportunities for targeted products.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs, including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
- Analysis of the current and future market competition in the global prostate cancer therapeutics market. Company profiles including a business description, a financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A) analysis, which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the Japanese prostate cancer therapeutics market.
- Understanding the treatment preferences of physicians according to disease state and across treatment flow.
- Assessing market sizing, forecasts and quantified growth opportunities in the BRIC prostate cancer therapeutics market up to 2020.
- Quantifying the patient population in the BRIC countries to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products.
- Identifying market entry points based on safety, efficacy and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of the current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look of at the disease pipeline and identifying the most promising paradigm shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

Table of Contents

1 Table of contents 3
1.1 List of Tables 7
1.2 List of Figures 8
2 Disease Overview 11
2.1 Overview 11
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 11
2.1.2 Jewett-Whitmore system 12
2.2 Epidemiology 12
2.3 Etiology 13
2.4 Symptoms 13
2.4.1 Localized or Locally Advanced Prostate Cancer 13
2.4.2 Metastatic Prostate Cancer 13
2.5 Diagnosis 14
2.5.1 Digital Rectal Examination 14
2.5.2 Prostate Specific Antigen Test 14
2.5.3 Transrectal Ultrasound 15
2.5.4 Prostate Biopsy 15
2.6 Pathology 15
2.6.1 Grading 15
2.7 Treatment 16
2.7.1 Watchful Waiting 16
2.7.2 Radiation therapy 16
2.7.3 Surgery 17
2.7.4 Hormone therapy 17
2.7.5 Chemotherapy Options 18
2.7.6 Other Treatments Being Studied 19
2.8 Treatment Guidelines 20
3 Market Characterization 21
3.1 BRIC (Brazil, Russia, India and China) 21
3.1.1 Market Size 21
3.1.2 Forecasts 26
3.2 Brazil 31
3.2.1 Market Size 31
3.2.2 Drivers and Restraints 36
3.2.3 Impact on the Market 37
3.2.4 Forecasts 38
3.2.5 Future Impact 43
3.3 Russia 44
3.3.1 Market Size 44
3.3.2 Drivers and Restraints 49
3.3.3 Impact on the Market 50
3.3.4 Forecasts 51
3.3.5 Future Impact 56
3.4 India 57
3.4.1 Market Size (2001-2009) 57
3.4.2 Drivers and Restraints 62
3.4.3 Impact on the Market 63
3.4.4 Forecasts (2010-2020) 64
3.4.5 Future Impact 69
3.5 China 70
3.5.1 Market Size (2001-2009) 70
3.5.2 Drivers and Restraints 75
3.5.3 Impact on the Market 76
3.5.4 Forecasts (2010-2020) 77
3.5.5 Future Impact 82
3.6 Key Takeaway 82
4 Competitor Assessment 83
4.1 Strategic Competitor Assessment 83
4.1.1 Overview 83
4.1.2 Benchmarking 83
4.1.3 Current Competitor Assessment 87
4.2 Product Profiles 89
4.2.1 Taxotere (docetaxel) 90
4.2.2 Casodex (Bicalutamide) 93
4.2.3 Zoladex (Goserelin) 97
4.2.4 Eligard (leuprolide acetate) 99
4.2.5 Lupron (Leuprolide acetate) 102
4.2.6 Firmagon (degarelix) 106
4.2.7 Novantrone (Mitoxantrone hydrochloride) 108
4.2.8 Emcyt (estramustine) 110
4.2.9 Trelstar (triptorelin) 111
4.2.10 Eulexin 112
4.2.11 Delestrogen 114
4.2.12 Gynodiol 115
4.2.13 Estrace tablet 116
4.2.14 Tace 117
4.2.15 Nilandrone 118
4.2.16 Premarin 119
5 Pipeline Assessment 120
5.1 Overview 120
5.2 Pipeline Analysis by Phase of Development 121
5.3 Pipeline by Mechanism of Action 122
5.4 Strategic Pipeline Assessment 123
5.4.1 Technology Trends Analytical Framework 123
5.5 Trends in Prostate Cancer Pipeline 124
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 124
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 124
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 124
5.6 Partners in Research and Development 125
5.6.1 Licensing Agreements by Phase of Development 125
5.6.2 Licensing Agreements by Geography 128
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 128
5.7 Most Promising Drugs’ Profiles 129
5.7.1 Provenge (sipuleucel-T) 131
5.7.2 Jevtana (cabazitaxel) 132
5.7.3 Aflibercept (VEGF Trap) 133
5.7.4 Ipilimumab 135
5.7.5 Abiraterone Acetate (CB7630) 136
5.7.6 Zibotentan (ZD4054) 138
5.7.7 Sprycel (dasatinib) 139
5.7.8 MDV3100 141
5.8 Prostate Cancer Pipeline - Pre-clinical Phase 143
5.9 Prostate Cancer Pipeline - Phase I 145
5.10 Prostate Cancer Pipeline - Phase II 147
5.11 Prostate Cancer Pipeline - Phase III 154
5.12 Key Takeaway 156
6 Unmet Need and Target Product Profile 157
6.1 Unmet Need 159
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 159
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 160
6.2 Opportunity for Target Product 161
6.3 Target Product Profile 163
6.3.1 Ideal Characteristics 163
6.3.2 Target Product Description 164
6.4 Key Takeaway 164
7 Strategic Assessment 165
7.1 Key Events Impacting the Future Market 165
7.2 Market Impact Analysis 166
7.3 Future Market Scenario 166
7.4 Company Analysis 168
7.4.1 Market Leadership 168
7.4.2 Future Players in the Market 168
7.5 Key Takeaway 169
8 Company Profiles 170
8.1 Sanofi-aventis 170
8.1.1 Business Description 170
8.1.2 Financial Overview 172
8.1.3 SWOT Analysis 172
8.1.4 Oncology Focus 177
8.2 Pfizer Inc. 178
8.2.1 Business Description 178
8.2.2 Financial Overview 179
8.2.3 SWOT Analysis 179
8.2.4 Oncology Focus 185
8.3 AstraZeneca 186
8.3.1 Business Description 186
8.3.2 Financial Overview 188
8.3.3 SWOT Analysis 188
8.3.4 Oncology Focus 192
8.4 Bristol-Myers Squibb 194
8.4.1 Business Description 194
8.4.2 Financial Overview 195
8.4.3 SWOT Analysis 195
8.4.4 Oncology Focus 200
8.5 Medivation 202
8.5.1 Business Description 202
8.5.2 SWOT Analysis 203
8.5.3 Oncology Focus 206
8.6 Takeda Pharmaceuticals 206
8.6.1 Business Description 206
8.6.2 SWOT Analysis 206
8.7 Dendreon Corporation 208
8.7.1 Business Description 208
8.7.2 SWOT Analysis 208
8.8 Johnson and Johnson 212
8.8.1 Business Description 212
8.8.2 SWOT Analysis 213
8.8.3 Oncology Focus 219
8.9 Auron Healthcare GmbH 220
8.9.1 Business Description 220
8.10 Oncogenex Pharmaceuticals, Inc. 221
8.10.1 Business Description 221
8.11 Agennix AG 221
8.11.1 Business Description 221
8.12 GTx, Inc. 221
8.12.1 Business Description 221
8.13 GlaxoSmithKline plc. 222
8.13.1 Business Description 222
8.13.2 Financial Overview 223
8.13.3 SWOT Analysis 223
8.13.4 Oncology Focus 229
9 M&A Analysis 231
9.1 Key Highlights 231
9.2 Key Deals’ Analysis 232
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 232
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 232
9.2.3 Tolmar Holding Acquires QLT USA from QLT 233
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 233
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 233
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 233
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 233
9.2.8 GPC Biotech Merges with Agennix 233
9.2.9 Eli Lilly Acquires ImClone 234
9.2.10 BBM Holdings Acquires YM BioSciences 234
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 234
9.3 M&A Deals by Geography 235
9.4 M&A Deals by Deal Size 235
10 Appendix 236
10.1 Market Definitions 236
10.2 Abbreviations 236
10.3 Research Methodology 238
10.3.1 Coverage 238
10.3.2 Secondary Research 239
10.3.3 Forecasting 239
10.3.4 Primary Research 242
10.3.5 Expert Panel validation 242
10.3.6 Contact Us 242
10.3.7 Disclaimer 242
10.3.8 Sources 243

1.1 List of Tables
Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 12
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14
Table 3: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2001-2009 21
Table 4: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2001-2009 22
Table 5: Prostate Cancer Therapeutics Market, BRIC, Patient Volume, 2001-2009 23
Table 6: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2001-2009 24
Table 7: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2009-2020 26
Table 8: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2009-2020 27
Table 9: Prostate Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 2009-2020 28
Table 10: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2009-2020 29
Table 11: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001-2009 31
Table 12:Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001-2009 32
Table 13: Prostate Cancer Therapeutics Market, Brazil, Patient Volume (’000s), 2001-2009 33
Table 14:Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns (’000s), 2001-2009 34
Table 15:Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009-2020 38
Table 16:Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009-2020 39
Table 17: Prostate Cancer, Brazil, Patient Volume (’000s), 2009-2020 40
Table 18: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns (’000s), 2009-2020 41
Table 19: Prostate Cancer, Russia, Sales Value ($m), 2001-2009 44
Table 20: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2001-2009 45
Table 21: Prostate Cancer, Russia, Patient Volume (Thousands), 2001-2009 46
Table 22: Prostate Cancer, Russia, Treatment Usage Patterns, 2001-2009 47
Table 23: Prostate Cancer, Russia, Sales Value ($m), 2009-2020 51
Table 24: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2009-2020 52
Table 25: Prostate Cancer, Russia, Patient Volume (Thousands), 2009-2020 53
Table 26: Prostate Cancer, Russia, Treatment Usage Patterns, 2009-2020 54
Table 27: Prostate Cancer, India, Sales Value ($m), 2001-2009 57
Table 28: Prostate Cancer, India, Annual Cost of Therapy ($), 2001-2009 58
Table 29: Prostate Cancer, India, Patient Volume (Thousands), 2001-2009 59
Table 30: Prostate Cancer, India, Treatment Usage Patterns, 2001-2009 60
Table 31: Prostate Cancer, India, Sales Value ($m), 2009-2020 64
Table 32: Prostate Cancer, India, Annual Cost of Therapy ($), 2009-2020 65
Table 33: Prostate Cancer, India, Patient Volume (Thousands), 2009-2020 66
Table 34: Prostate Cancer, India, Treatment Usage Patterns, 2009-2020 67
Table 35: Prostate Cancer, China, Sales Value ($m), 2001-2009 70
Table 36: Prostate Cancer, China, Annual Cost of Therapy ($), 2001-2009 71
Table 37: Prostate Cancer, China, Patient Volume (Thousands), 2001-2009 72
Table 38: Prostate Cancer, China, Treatment Usage Patterns, 2001-2009 73
Table 39: Prostate Cancer, China, Sales Value ($m), 2009-2020 77
Table 40: Prostate Cancer, China, Annual Cost of Therapy ($), 2009-2020 78
Table 41: Prostate Cancer, China, Patient Volume (Thousands), 2009-2020 79
Table 42: Prostate Cancer, China, Treatment Usage Patterns, 2009-2020 80
Table 43: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 84
Table 44: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 85
Table 45: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 86
Table 46: Prostate Cancer, BRIC, Benchmarking Major Marketed Products, 2010 89
Table 47: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 94
Table 48: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 99
Table 49: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 100
Table 50: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 101
Table 51: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products 103
Table 52: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010 104
Table 53: Prostate Cancer, Global, Licensing Agreements, 2009-2010 127
Table 54: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 129
Table 55: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 129
Table 56: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 143
Table 57: Prostate Cancer, Global, Phase I Pipeline, August 2010 145
Table 58: Prostate Cancer, Global, Phase II Pipeline, August 2010 147
Table 59: Prostate Cancer, Global, Phase III Pipeline, August 2010 154
Table 60: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 163
Table 61: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 164
Table 62: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 219
Table 63: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 220
Table 64: Prostate Cancer, Global, M&A Deals by Geography, 2010 231

1.2 List of Figures
Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 20
Figure 2: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2001-2009 21
Figure 3: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2001-2009 22
Figure 4: Prostate Cancer Therapeutics Market, BRIC, Patient Volume, 2001-2009 23
Figure 5: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2001-2009 24
Figure 6: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2009-2020 26
Figure 7: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2009-2020 27
Figure 8: Prostate Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 2009-2020 28
Figure 9: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2009-2020 29
Figure 10: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001-2009 31
Figure 11: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001-2009 32
Figure 12: Prostate Cancer Therapeutics Market, Brazil, Patient Volume (’000s), 2001-2009 33
Figure 13: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns (’000s), 2001-2009 34
Figure 14: Prostate Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009 36
Figure 15: Prostate Cancer Therapeutics Market, Brazil, Historical Events Impact on the Market, 2010 37
Figure 16: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009-2020 38
Figure 17: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009-2020 39
Figure 18: Prostate Cancer Therapeutics Market, Brazil, Patient Volume (’000s), 2009-2020 40
Figure 19: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns (’000s), 2009-2020 41
Figure 20: Prostate Cancer Therapeutics Market, Brazil, Future Events Expected to Impact the Market, 2010 43
Figure 21: Prostate Cancer, Russia, Sales Value ($m), 2001-2009 44
Figure 22: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2001-2009 45
Figure 23: Prostate Cancer, Russia, Patient Volume (Thousands), 2001-2009 46
Figure 24: Prostate Cancer, Russia, Treatment Usage Patterns, 2001-2009 47
Figure 25: Prostate Cancer, Russia, Market Drivers and Restraints, 2009 49
Figure 26: Prostate Cancer, Russia, Historical Events Impact on the Market, 2010 50
Figure 27: Prostate Cancer, Russia , Sales Value ($m), 2009-2020 51
Figure 28: Prostate Cancer, Russia , Annual Cost of Therapy ($), 2009-2020 52
Figure 29: Prostate Cancer, Russia , Patient Volume (Thousands), 2009-2020 53
Figure 30: Prostate Cancer, Russia, Treatment Usage Patterns, 2009-2020 54
Figure 31: Prostate Cancer, Russia, Future Events Expected to Impact the Market, 2010 56
Figure 32: Prostate Cancer, India, Sales Value ($m), 2001-2009 57
Figure 33: Prostate Cancer, India, Annual Cost of Therapy ($), 2001-2009 58
Figure 34: Prostate Cancer, India, Patient Volume (Thousands), 2001-2009 59
Figure 35: Prostate Cancer, India, Treatment Usage Patterns, 2001-2009 60
Figure 36: Prostate Cancer, India, Market Drivers and Restraints, 2009 62
Figure 37: Prostate Cancer, India, Historical Events and Their Impact on the Market, 2010 63
Figure 38: Prostate Cancer, India, Sales Value ($m), 2009-2020 64
Figure 39: Prostate Cancer, India, Annual Cost of Therapy ($), 2009-2020 65
Figure 40: Prostate Cancer, India, Patient Volume (Thousands), 2009-2020 66
Figure 41: Prostate Cancer, India, Treatment Usage Patterns, 2009-2020 67
Figure 42: Prostate Cancer, India, Future Events Expected to Affect the Market, 2010 69
Figure 43: Prostate Cancer, China, Sales Value ($m), 2001-2009 70
Figure 44: Prostate Cancer, China, Annual Cost of Therapy ($), 2001-2009 71
Figure 45: Prostate Cancer, China, Patient Volume (Thousands), 2001-2009 72
Figure 46: Prostate Cancer, China, Treatment Usage Patterns, 2001-2009 73
Figure 47: Prostate Cancer, China, Market Drivers and Restraints, 2009 75
Figure 48: Prostate Cancer, China, Historical Events and Their Impact on the Market, 2010 76
Figure 49: Prostate Cancer, China, Sales Value ($m), 2009-2020 77
Figure 50 Prostate Cancer, China, Annual Cost of Therapy ($), 2009-2020 78
Figure 51: Prostate Cancer, China, Patient Volume (Thousands), 2009-2020 79
Figure 52: Prostate Cancer, China, Treatment Usage Patterns, 2009-2020 80
Figure 53: Prostate Cancer, China, Future Events Expected to Impact the Market, 2010 82
Figure 54: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 87
Figure 55: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 88
Figure 56: Prostate Cancer, Global, Taxotere, Chemical Structure 90
Figure 57: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 92
Figure 58: Prostate Cancer, Global, Casodex, Chemical Structure 93
Figure 59: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 97
Figure 60: Prostate Cancer, Global, Zoladex, Chemical Structure 98
Figure 61: Prostate Cancer, Global, Eligard , Chemical Structure 99
Figure 62: Prostate Cancer, Global, Lupron, Chemical Structure 102
Figure 63: Prostate Cancer, Global, Firmagon, Chemical Structure 106
Figure 64: Prostate Cancer, Global, Novatrone, Chemical Structure 108
Figure 65: Prostate Cancer, Global, Emcyt, Chemical Structure 110
Figure 66: Prostate Cancer, Global, Trelstar, Chemical Structure 111
Figure 67: Prostate Cancer, Global, Eulexin, Chemical Structure 112
Figure 68: Prostate Cancer, Global, Delestrogen, Chemical Structure 114
Figure 69: Prostate Cancer, Global, Gynodiol, Chemical Structure 115
Figure 70: Prostate Cancer, Global, Estrace, Chemical Structure 116
Figure 71: Prostate Cancer, Global, Tace, Chemical Structure 117
Figure 72: Prostate Cancer, Global, Nilandrone, Chemical Structure 118
Figure 73: Prostate Cancer, Global, Premarin, Chemical Structure 119
Figure 74: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 120
Figure 75: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 121
Figure 76: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 122
Figure 77: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 123
Figure 78: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 124
Figure 79: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 125
Figure 80: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 128
Figure 81: Prostate Cancer, Global, Aflibercept, Chemical Structure 133
Figure 82: Prostate Cancer, Global, Abiraterone, Chemical Structure 136
Figure 83: Prostate Cancer, Global, Zibotentan, Chemical Structure 138
Figure 84: Prostate Cancer, Global, MDV3100, Chemical Structure 141
Figure 85: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 157
Figure 86: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 158
Figure 87: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 158
Figure 88: Prostate Cancer, BRIC, Prostate Cancer, Opportunity and Unmet Need, 2010 159
Figure 89: Prostate Cancer, BRIC, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 162
Figure 90: Prostate Cancer, BRIC, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 162
Figure 91: Prostate Cancer, Global, Key Events Impacting the Future Market 165
Figure 92: Prostate Cancer, BRIC, Implications for Future Market Competition, 2010 166
Figure 93: Prostate Cancer, Global, Future Players in the Market, 2010 168
Figure 94:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 170
Figure 95: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 171
Figure 96: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 172
Figure 97: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 177
Figure 98: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 179
Figure 99: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 185
Figure 100: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 186
Figure 101: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 187
Figure 102: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 188
Figure 103: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 192
Figure 104: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 193
Figure 105: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 193
Figure 106: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 194
Figure 107: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 195
Figure 108: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 200
Figure 109: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 201
Figure 110: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 203
Figure 111: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 206
Figure 112: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 208
Figure 113: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 213
Figure 114: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 220
Figure 115: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 223
Figure 116: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 229
Figure 117: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 230
Figure 118: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 235
Figure 119: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 235
Figure 120: GlobalData Market Forecasting Model 241

Back to Top